‘No Decision’ On Sandoz As Novartis Continues To Explore Options

Update To Strategic Review Likely By The End Of The Year

 
• By Chloe Kent
  
Man standing among swirling arrows pointing in different directions
Novartis has many decisions to make as it decides Sandoz's fate • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business